| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
i
|
|
|
|
Acknowledgements
|
|
v
|
|
| Thursday, April 19, 2012 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
1 ATOMIC: 97% RVR FOR PSI-7977 + PEG/RBV × 12 WEEK REGIMEN IN HCV GT1: AN END TO RESPONSE-GUIDED THERAPY?
|
K.V. Kowdlev,
E. Läwitz,
I. Crespo,
T. Hassanein,
M. Davis,
M. DeMicco,
D.R. Nelson,
D. Bernstein,
N.H. Afdhal,
I. Jacobson,
J. Vierling,
S. Gordon,
J.K. Anderson,
R.H. Hyland,
R.G. Hindes,
C. Baker,
R. Sorensen,
E. Albanis,
W.T. Symonds,
M.M. Berrey,
ATOMIC Investigators
et al.
|
S1
|
|
|
|
2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL
|
S. Zeuzem,
T. Berg,
E. Gane,
P. Ferenci,
G.R. Foster,
M.W. Fried,
C. Hezode,
G. Hirschfield,
I. Jacobson,
I. Nikitin,
P. Pockros,
F. Poordad,
O. Lenz,
M. Peeters,
V. Sekar,
G. De Smedt,
M. Beumont-Mauviel
et al.
|
S1-S2
|
|
|
|
3 ACTIVATED INTESTINAL MACROPHAGES IN LIVER CIRRHOSIS PRODUCE NITRIC OXIDE AND DISRUPT INTESTINAL BARRIER FUNCTION
|
J. du Plessis,
L. Roos,
T. Slavik,
P.I. Stivaktas,
M. Nieuwoudt,
S.G. van Wyk,
W.A. Vieira,
E. Pretorius,
M. Beukes,
S.W. van der Merwe
et al.
|
S1
|
|
|
|
4 DIFFERENT ROLES OF JNK1 AND JNK2 IN THE DEVELOPMENT OF NASH AND HCC
|
F.J. Cubero,
G. Zhao,
Y.A. Nevzorova,
M. Hatting,
O. Drvarov,
M. Al Masaoudi,
N. Gassler,
C. Liedtke,
C. Trautwein
et al.
|
S2-S3
|
|
|
|
5 THE EMERGING IMPACT OF HEPATOCELLULAR CARCINOMA ARISING ON A BACKGROUND OF NAFLD
|
H. Reeves,
E. Villa,
S. Bellentani,
E. Dionigi,
J.-F. Dufour,
C. de Oliveira,
A. Fracanzani,
A. Barcheti,
P. Merle,
J. Boursier,
J. Schattenberg,
L. Fedchuk,
C. Holst,
V. Ratziu,
on behalf of the FLIP Investigators
et al.
|
S3
|
|
|
|
6 BARIATRIC SURGERY AN EFFICIENT TREATMENT FOR PATIENT WITH STEATOHEPATITIS
|
G. Lassailly,
R. Caïazzo,
D. Buob,
L. Arnalsteen,
A. Louvet,
E. Leteurtre,
M. Colin,
S. Dharancy,
A. Hollebecque,
V. Canva-Delcambre,
P. Deltenre,
F. Pattou,
P. Mathurin
et al.
|
S3
|
|
|
|
7 PSI-7977 PROTON AND ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3
|
E. Lawitz,
E. Gane,
C. Stedman,
J.P. Lalezari,
T. Hassanein,
K.V. Kowdley,
F.F. Poordad,
A.M. Sheikh,
N.H. Afdal,
D.E. Bernstein,
E. DeJesus,
B. Freilich,
D.R. Nelson,
D.T. Dieterich,
I.M. Jacobson,
D. Jensen,
G.A. Abrams,
J.M. Darling,
M. Rodriguez-Torres,
K.R. Reddy,
M.S. Sulkowski,
N.H. Bzowej,
M.P. DeMicco,
J.S. Strohecker,
R.H. Hyland,
J.K. Anderson,
C. Baker,
S. Kirven,
R.G. Hindes,
E. Albanis,
W.T. Symonds,
M.M. Berrey
et al.
|
S4
|
|
|
|
8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)
|
C. Hezode,
C. Dorival,
F. Zoulim,
T. Poynard,
P. Mathurin,
S. Pol,
D. Larrey,
P. Cacoub,
V. de Ledinghen,
M. Bourlière,
P.H. Bernard,
G. Riachi,
L. Alric,
D. Samuel,
Y. Barthe,
H. Fontaine,
F. Carrat,
J.-P. Bronowicki,
ANRS C020 CUPIC study group
et al.
|
S4
|
|
|
|
9 TMC435 IN PATIENTS INFECTED WITH HCV GENOTYPE 1 WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: VIROLOGIC ANALYSES OF THE ASPIRE TRIAL
|
O. Lenz,
B. Fevery,
L. Vijgen,
J. Verbeeck,
M. Peeters,
M. Beumont-Mauviel,
S. Zeuzem,
G. Picchio
et al.
|
S5
|
|
|
|
10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB
|
S. Zeuzem,
S. Arora,
B. Bacon,
T. Box,
M. Charlton,
M. Diago,
D. Dieterich,
R.E. Mur,
G. Everson,
M. Fallon,
P. Ferenci,
R. Flisiak,
J. George,
R. Ghalib,
N. Gitlin,
A. Gladysz,
S. Gordon,
S. Greenbloom,
T. Hassanein,
I. Jacobson,
L. Jeffers,
K. Kowdley,
E. Lawitz,
S.S. Lee,
B. Leggett,
S. Lueth,
D. Nelson,
P. Pockros,
M. Rodriguez-Torres,
V. Rustgi,
L. Serfaty,
M. Sherman,
M. Shiffman,
R. Sola,
M. Sulkowski,
H. Vargas,
J. Vierling,
B. Yoffe,
L. Ishak,
D. Fontana,
D. Xu,
T. Gray,
A. Horga,
J. Hillson,
J.C. Lopez-Talavera,
A. Muir,
EMERGE Study Group
et al.
|
S5-S6
|
|
|
|
11 SUSTAINED VIROLOGIC RESPONSE (SVR) IN PRIOR PEGINTERFERON/RIBAVIRIN (PR) TREATMENT FAILURES AFTER RETREATMENT WITH BOCEPREVIR (BOC)-+-PR: THE PROVIDE STUDY INTERIM RESULTS
|
J.P. Bronowicki,
M. Davis,
S. Flamm,
S. Gordon,
E. Lawitz,
E. Yoshida,
J. Galati,
V. Luketic,
J. McCone,
I. Jabobson,
P. Marcellin,
A. Muir,
F. Poordad,
L.D. Pedicone,
W. Deng,
M. Treitel,
J. Wahl,
J. Vierling
et al.
|
S6
|
|
|
|
12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS
|
D.R. Nelson,
E. Lawitz,
V. Bain,
N. Gitlin,
T. Hawkins,
P. Marotta,
K. Workowski,
S. Flamm,
P.S. Pang,
J.G. McHutchison,
J. McNally,
P. Urbanek,
E.M. Yoshida
et al.
|
S6-S7
|
|
|
|
13 A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS
|
E. Lawitz,
F. Poordad,
K.V. Kowdley,
D. Jensen,
D.E. Cohen,
S. Siggelkow,
K. Wikstrom,
L. Larsen,
R.M. Menon,
T. Podsadecki,
B. Bernstein
et al.
|
S7
|
|
|
|
14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN
|
F. Suzuki,
K. Ikeda,
J. Toyota,
Y. Karino,
T. Ohmura,
K. Chayama,
S. Takahashi,
Y. Kawakami,
H. Ishikawa,
H. Watanabe,
W. Hu,
F. McPhee,
E. Hughes,
H. Kumada
et al.
|
S7-S8
|
|
|
|
15 LANDSCAPE OF SOMATIC MUTATION IN HEPATOCELLULAR CARCINOMA
|
C. Guichard,
S. Imbeaud,
G. Amaddeo,
I. Ben Maad,
E. Letouze,
L. Pelletier,
M. Letexier,
P. Bioulac-Sage,
J. Calderaro,
J. Zucman-Rossi
et al.
|
S8
|
|
|
|
16 HCV TRANSGENE EFFICIENTLY PROMOTES INFLAMMATION-ASSOCIATED HEPATOCARCINOGENESIS IN A NEW MOUSE MODEL
|
E. Ella,
O. Pappo,
D. Olam,
L. Mizrahi,
T. Schnitzer Perlman,
E. Galun,
D. Goldenberg
et al.
|
S8
|
|
|
|
17 STRAIN-SPECIFIC DISPARITY MODIFIES HEPATOCELLULAR CARCINOMA INITIATION IN ABCB4-DEFICIENT MICE
|
S.N. Weber,
A. Bohner,
F. Lammert
|
S8-S9
|
|
|
|
18 P2Y2 RECEPTOR FUNCTION AGGRAVATES ACUTE HEPATITIS BY REGULATING NEUTROPHIL INFILTRATION AND HEPATOCYTE SURVIVAL
|
K. Ayata,
M. Idzko,
P. Hasselblatt
|
S9
|
|
|
|
19 HOW ARE HEPATOCYTES PRIMED FOR TGF-β MEDIATED APOPTOSIS? BONE MORPHOGENETIC PROTEIN (BMP)-9 AS DEADLY CO-FACTOR IN VITRO AND IN VIVO
|
K. Breitkopf-Heinlein,
Q. Li,
A. Mueller,
P. ten Dijke,
S. Dooley
et al.
|
S9
|
|
|
|
20 DEFICIENCIES OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2 BETA IN VIVO CAUSES REDUCED SYSTEMIC LIPIDS AND LIPOPROTEINS CONCOMITANT WITH INCREASED HEPATIC APOPTOSIS AND INFLAMMATION
|
W. Xu,
S. Tuma,
N. Katava,
A. Pathil-Warth,
W. Stremmel,
W. Chamulitrat
et al.
|
S9-S10
|
|
|
|
21 SPECIFIC CELL CYCLES CONTROL HEPATOCYTES POLYPLOIDIZATION DURING NORMAL AND PATHOLOGICAL STATES
|
G. Gentric,
V. Paradis,
D. Couton,
G. Merlen,
S. Celton-Morizur,
C. Desdouets
et al.
|
S10
|
|
|
|
22 APOPTOTIC MIRNA-21/PDCD4 SIGNALING IN RAT HEPATOCYTES: DOSE-DEPENDENT EFFECT OF DEOXYCHOLIC ACID
|
R.E. Castro,
M.B. Afonso,
D.M.S. Ferreira,
P.M. Borralho,
C.M.P. Rodrigues
et al.
|
S10
|
|
|
|
23 NON-ALCOHOLIC FATTY LIVER DISEASE IS A PREDICTOR OF CARDIOVASCULAR DISEASES
|
M. Stepanova,
Z.M. Younossi
|
S11
|
|
|
|
24 MISSED OPPORTUNITIES FOR HBV SCREENING: RESULTS OF A LARGE SCREENING CAMPAIGN IN THE COMMUNITY, FRANCE 2011
|
J. Bottero,
A. Boyd,
M. Lemoine,
J. Gozlan,
A. Collignon,
N. Boo,
P. Dhotte,
B. Varsat,
G. Muller,
O. Cha,
J. Nau,
P. Campa,
O. Picard,
B. Silbermann,
M. Bary,
P.-M. Girard,
K. Lacombe
et al.
|
S11
|
|
|
|
25 SOCIETAL BURDEN IN PATIENTS WITH CHRONIC HEPATIC DISEASES: THE COME STUDY RESULTS
|
S. Fagiuoli,
L. Scalone,
R. Ciampichini,
F. Fusco,
L. Gaeta,
A. Del Prete,
I. Gardini,
L.G. Mantovani
et al.
|
S11-S12
|
|
|
|
26 LIVER RELATED DEATHS IN HIV-INFECTED PATIENTS BETWEEN 2000 AND 2010. RESULTS OF THE FRENCH NATIONAL SURVEY “ANRS EN20 MORTALITE 2010”
|
P. Cacoub,
E. Rosenthal,
D. Salmon,
C. Roussillon,
F. Bonnet,
A. Aouba,
T. May,
D. Costagliola,
G. Chene,
P. Morlat
et al.
|
S12
|
|
|
|
27 LONG TERM MORTALITY OF ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND ADVANCED FIBROSIS IN THE US GENERAL POPULATION
|
D. Kim,
W.R. Kim,
H.J. Kim
|
S12
|
|
|
|
28 EFFECT OF HEPATITIS C COINFECTION ON CAUSE-SPECIFIC MORTALITY FOLLOWING HIV SEROCONVERSION IN THE PRE-CART AND CART ERAS
|
J. van der Helm,
R. Geskus,
C. Sabin,
L. Meyer,
J. del Amo,
G. Chène,
M. Dorrucci,
R. Muga,
K. Porter,
M. Prins,
on behalf of CASCADE Collaboration in EuroCoord
et al.
|
S13
|
|
|
|
29 BODY FAT DISTRIBUTION AND RISK FACTORS FOR FIBROSIS IN PATIENTS WITH ALCOHOLIC LIVER DISEASE
|
S. Naveau,
A.-S. Dobrin,
A. Balian,
M. Njiké-Nakseu,
P. Nohra,
A. Asnacios,
S. Prevot,
G. Perlemuter
et al.
|
S13
|
|
|
|
30 LOW EFFICACY OF CURRENT NUCLEIC ACID TESTING (NAT) ASSAYS FOR THE IDENTIFICATION OF OCCULT HBV INFECTION (OBI) AND CONSEQUENCES FOR SAFETY OF BLOOD SUPPLY
|
M. Spreafico,
B. Foglieni,
A. Berzuini,
L. Raffaele,
I. Guarnori,
D. Prati
et al.
|
S13-S14
|
|
|
|
31 MONOCYTE/MACROPHAGE PERIBILIARY RECRUITMENT BY PKHD1-DEFECTIVE CHOLANGIOCYTES INDUCES EXPRESSION OF αvβ6 INTEGRIN ON BILIARY CYSTS VIA TGF-β1 AND TNF-α IN CONGENITAL HEPATIC FIBROSIS
|
L. Fabris,
L. Locatelli,
C. Spirlì,
M. Cadamuro,
S. Lecchi,
C. Morell,
Y. Popov,
D. Schuppan,
M. Strazzabosco
et al.
|
S14
|
|
|
|
32 GENOME WIDE ANALYSIS IDENTIFIES MITOTIC RECOMBINATION AS CAUSE OF SOMATIC LOSS OF HETEROZYGOSITY IN CYSTS FROM POLYCYSTIC LIVER DISEASE PATIENTS
|
M. Janssen,
R. Pfundt,
J.P.H. Drenth
|
S14
|
|
|
|
33 NOTCH SIGNALLING WITHIN THE TUMOUR-STROMAL MICROENVIRONMENT DRIVES PROGRESSION OF CHOLANGIOCARCINOMA WHILST PATHWAY INHIBITION ENHANCES CHEMOSENSITIVITY
|
A. Robson,
R.V. Guest,
L. Boulter,
A. Pellicoro,
O. Sansom,
S. Forbes
et al.
|
S15
|
|
|
|
34 UPREGULATION OF MIR-506 LEADS TO DECREASED AE2 EXPRESSION IN BILIARY EPITHELIUM OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS
|
J.M. Banales,
E. Sáez,
M. Úriz,
P. Splinter,
P.S. Tietz Bogert,
J. Prieto,
J.F. Medina,
N.F. LaRusso
et al.
|
S15
|
|
|
|
35 FINE MAPPING OF THE IL-2/IL-21 AND IL2RA LOCI IN PRIMARY SCLEROSING CHOLANGITIS
|
B. Srivastava,
G. Mells,
H. Cordell,
A. Murithii,
M. Brown,
E. Ellinghaus,
A. Franke,
T.H. Karlsen,
R. Sandford,
G.J. Alexander,
R. Chapman,
S. Rushbrook,
E. Melum,
UK-PSC Consortium
et al.
|
S15-S16
|
|
|
|
36 PDX-1/HES-1 INTERACTIONS DETERMINE CHOLANGIOCYTE PROLIFERATIVE RESPONSE TO INJURY: THE SIGNIFICANCE FOR SCLEROSING CHOLANGITIS
|
M. Marzioni,
S. Saccomanno,
L. Agostinelli,
C. Rychlicki,
I. Pierantonelli,
M. Trauner,
P. Fickert,
T. Müller,
K. Shanmukhappa,
G. Alpini,
L. Trozzi,
S. De Minicis,
C. Candelaresi,
G. Svegliati Baroni,
A. Benedetti
et al.
|
S16
|
|
|
|
37 ACTIVATION OF INTESTINAL FGF15 SIGNALING BY INFLAMMATION LEADS TO CHANGES IN HEPATIC BILE ACID METABOLISM AND A TOXIC BILE PROFILE IN DSS TREATED MICE
|
M. Rau,
J. Schmitt,
B. Stieger,
K. Leucht,
A. Cee,
J.J.G. Marin,
M.J. Monte,
B. Müllhaupt,
G. Rogler,
A. Geier
et al.
|
S16-S17
|
|
|
|
38 SERUM METABOLOMIC PROFILING IN PATIENTS WITH CHOLESTATIC PRURITUS
|
A. Pares,
M. Perez-Cormenzana,
R. Mayo,
A. Bennasar,
A. Mas,
A. Castro
et al.
|
S17
|
|
|
|
39 EPIGENETIC CONTROL OF HEPATITIS B VIRUS REPLICATION AND FARNESOID X RECEPTOR ALPHA EXPRESSION BY HISTONE DEACETYLASES 3
|
X. Zhang,
H. Liu,
B. Wang,
Z. Ma,
J. Zhang,
D. Yang,
J. Schlaak,
M. Roggendorf,
M. Lu
et al.
|
S17
|
|
|
|
40 HLA-B27 HAS A DOMINANT ROLE IN RESTRICTING STRONG CD8+ T CELL RESPONSES AND DRIVING VIRAL ESCAPE IN HEPATITIS B VIRUS INFECTION
|
M.M. Kiraithe,
K. Nitschke,
D. Price,
E. Gostick,
H.E. Blum,
R. Thimme,
C. Neumann-Haefelin
et al.
|
S17-S18
|
|
|
|
41 IL6, IL6-INDUCED MIRNAS AND HNF1A/HNF4A AND THE EPIGENETIC CONTROL OF CCCDNA TRANSCRIPTION
|
C. Scisciani,
N. Pediconi,
A. Palumbo,
J. Lucifora,
F. Guerrieri,
S. Rose-John,
U. Protzer,
M. Levrero,
L. Belloni
et al.
|
S18
|
|
|
|
42 PEGYLATED-INTERFERON-ALPHA ALONE OR IN COMBINATION WITH ENTECAVIR RESTORES ISG RESPONSIVENESS AND REDUCES INTRAHEPATIC VIRAL LOADS AND ANTIGENEMIA IN HEPATITIS B VIRUS INFECTED HUMANIZED MICE
|
L. Allweiss,
M. Lütgehetmann,
T. Volz,
T. Bornscheuer,
A.W. Lohse,
J. Petersen,
H. Ma,
K. Klumpp,
S. Fletcher,
M. Dandri
et al.
|
S18-S19
|
|
|
|
43 INTERLEUKIN-28B GENE POLYMORHISM MAY AFFECT THE NATURAL COURSE OF HEPATITIS B AND DELTA VIRUS INFECTIONS
|
A.M. Bozdayi,
T. Ozturk,
S. Altuntas,
S.C. Karatayli,
E. Karatayli,
C. Inci,
K. Cinar,
R. Albayrak,
M. Ozkan,
Y. Kendal,
R. Idilman,
C. Yurdaydin
et al.
|
S19
|
|
|
|
44 INDUCTION OF AN EARLY PATHOGEN RECOGNITION RECEPTOR EXPRESSION AND ANTIVIRAL CYTOKINE RESPONSE IN HUMAN HEPATOCYTES AFTER HEPATITIS B VIRUS INFECTION
|
S. Luangsay,
M. Ait-Goughoulte,
M. Gruffaz,
N. Isorce,
S. Fletcher,
M. Tommasino,
D. Durantel,
F. Zoulim
et al.
|
S19
|
|
|
|
45 RAPID AND EFFICIENT ANTIGEN PROCESSING AND PRESENTATION OF A PROTECTIVE AND IMMUNODOMINANT HLA-B*27-RESTRICTED HEPATITIS C VIRUS-SPECIFIC CD8+ T CELL EPITOPE
|
J. Schmidt,
A.K.N. Iversen,
S. Tenzer,
E. Gostick,
D.A. Price,
V. Lohmann,
P. Bowness,
H. Schild,
H.E. Blum,
P. Klenerman,
C. Neumann-Haefelin,
R. Thimme
et al.
|
S19-S20
|
|
|
|
46 IMMUNOLOGICAL PROFILES OF NON-RESPONDER AND RELAPSER PATIENTS WITH CHRONIC HCV INFECTION TREATED WITH STANDARD OF CARE THERAPY
|
B. Oliviero,
D. Mele,
E. Degasperi,
S. Varchetta,
A. Aghemo,
M.G. Rumi,
C. Tinelli,
M. Colombo,
M.U. Mondelli
et al.
|
S20
|
|
| Friday, April 20, 2012 |
| |
Article Title |
Author(s) |
Pages |
|
|
|
47 EFFICACY AND SAFETY OF PROTEASE INHIBITORS FOR SEVERE HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A FIRST MULTICENTRIC EXPERIENCE
|
A. Coilly,
B. Roche,
D. Botta-Fridlund,
V. Leroy,
P.G. Pageaux,
S.N. Si-Ahmed,
T.M. Antonini,
D. Samuel,
J.-C. Duclos-Vallee
et al.
|
S21
|
|
|
|
48 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED CONTROLLED GERMAN HEP-NET ACUTE HCV-III STUDY
|
K. Deterding,
N. Grüner,
P. Buggisch,
J. Wiegand,
P. Galle,
U. Spengler,
H. Hinrichsen,
T. Berg,
A. Potthoff,
N. Malek,
H. Diepolder,
S. Feyerabend,
M. Cornberg,
M.C. Jung,
M.P. Manns,
H. Wedemeyer,
The Hep-Net Acute HCV-Study group
et al.
|
S21
|
|
|
|
49 GALLBLADDER IS A HIGHLY AVAILABLE SOURCE OF STEM CELLS WITH MULTIPLE ENDODERMIC MATURE FATES POTENTIALITY
|
G. Carpino,
V. Cardinale,
R. Gentile,
P. Onori,
R. Semeraro,
A. Franchitto,
D. Bosco,
A. Iossa,
C. Napoletano,
G. D'Argenio,
M. Nuti,
N. Caporaso,
P.B. Berloco,
L. Reid,
E. Gaudio,
D. Alvaro
et al.
|
S22
|
|
|
|
50 BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS
|
J. Mallolas,
S. Pol,
A. Rivero,
H. Fainboim,
C. Cooper,
J. Slim,
S. Thompson,
J. Wahl,
W. Greaves,
M. Sulkowski
et al.
|
S22
|
|
|
|
51 GUT MICROBIOTA TRANSPLANTATION DEMONSTRATES ITS CAUSAL ROLE IN THE DEVELOPMENT OF TYPE 2 DIABETES AND FATTY LIVER
|
T. Le Roy,
M. Llopis,
A. Bruneau,
S. Rabot,
C. Bevilacqua,
P. Martin,
F. Walker,
A. Bado,
G. Perlemuter,
A.-M. Cassard-Doulcier,
P. Gérard
et al.
|
S23
|
|
|
|
52 DESCRIPTION OF AN AUTOMATED LOW-FLOW ASCITES (ALFA) PUMP SYSTEM FOR THE TREATMENT OF REFRACTORY ASCITES IN PATIENTS WITH CIRRHOSIS. PRELIMINARY REPORT
|
P. Bellot,
M. Welker,
G. Soriano,
M. von Schaewen,
B. Appenrodt,
R. Weist,
R. Tzonev,
S. Handshiev,
C. Verslype,
S. Zeuzem,
C. Moench,
C. Guarner,
E. Schott,
T. Sauerbruch,
A. Petrov,
K. Katzarov,
F. Nevens,
J. Such
et al.
|
S23
|
|
|
|
53 TLR2 AND TLR7/8 ACTIVATION PREDICT POST PARTUM HBV FLARES
|
K. Visvanathan,
N. Skinner,
S. Locarnini,
S. Bowden,
S. Lewin,
M. Giles,
J. Sasadeusz
et al.
|
S23-S24
|
|
|
|
54 PRESENCE OF ONLY WILDTYPE VIRUS IS THE STRONGEST DETERMINANT OF HBVDNA UNDETECTABILITY AND HBSAG CLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON
|
M.J. Sonneveld,
V. Rijckborst,
S. Zeuzem,
E.J. Heathcote,
K. Simon,
H. Senturk,
S.D. Pas,
B.E. Hansen,
H.L. Janssen
et al.
|
S24
|
|
|
|
55 FUTILITY RULES IN TELAPREVIR COMBINATION TREATMENT
|
I.M. Jacobson,
D.J. Bartels,
L. Gritz,
T.L. Kieffer,
S. De Meyer,
F. Tomaka,
L. Bengtsson,
D. Luo,
B.S. Adiwijaya,
R.S. Kauffman,
G. Picchio,
N. Adda
et al.
|
S24
|
|
|
|
56 DYNAMICS OF HCV QUASISPECIES DURING TELAPREVIR TREATMENT DISSECTED USING ULTRA-DEEP PYROSEQUENCING: TREATMENT FAILURE IN 100% OF GENOTYPE 1A PATIENTS
|
P. Pinson,
P. Trimoulet,
J. Papuchon,
J. Foucher,
J. Vergniol,
F. Chermak,
L. Wittkop,
W. Merrouche,
S. Reigadas,
M. Kann,
H. Fleury,
V. de Lédinghen
et al.
|
S25
|
|
|
|
57 MINIMAL-LENGTH SHRNAS ARE POTENT INHIBITORS OF HEPATITIS C VIRUS IN HCV-INFECTED CHIMERIC MICE
|
A. Dallas,
H. Ma,
H. Ilves,
J. Shorenstein,
M. Behlke,
S.-P. Wong,
R. Harbottle,
I. Maclachlan,
S. Kazakov,
S. Sankuratri,
K. Klumpp,
B.H. Johnston
et al.
|
S25
|
|
|
|
58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION
|
H.W. Reesink,
H.L.A. Janssen,
S. Zeuzem,
E. Lawitz,
M. Rodriguez-Torres,
K. Patel,
A. Chen,
C. Davis,
B. King,
A. Levin,
M.R. Hodges
et al.
|
S26
|
|
